Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
NEW YORK, May 02, 2018 -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that management will present a corporate overview at Deutsche Bank’s 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 10:40 a.m. ET.
A live audio webcast of the presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the company's website for two weeks following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome in 2017 and completed a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of epileptic encephalopathies and in 2017 initiated a Phase 1b/2a trial of OV935.
For more information on Ovid, please visit http://www.ovidrx.com/.
Contacts:
Ovid Therapeutics Inc.
Lora Pike
Senior Director, Investor Relations & Public Relations
[email protected]
OR
Investors:
Burns McClellan
Steve Klass, 212-213-0006
[email protected]
